InMed Pharmaceuticals Inc. (IMLFF) Files Patent Application for its Cannabinoid Biosynthesis Program

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty (“PCT”) application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. This application will provide protection of the biosynthesis technology in over 150 different countries including the United States and claims a priority date from September 5, 2017(PCT/CA2018/051074). The PCT filing, which is a conversion from the provisional patent filed in September 2017, is an important step in providing intellectual and commercial protection for InMed’s biosynthesis platform technology.

“With the conversion of this patent application, we are continuing the process of pursuing commercial protection for our biosynthesis platform technology.  As we undertake scale-up activities towards commercialization, today’s patent announcement is an important step forward for the Company,” said Dr. Eric Hsu, Ph.D., InMed’s Vice President of Preclinical Research and Development.  Dr. Hsu continued, “This application protects our effort to modulate E. coli’s own internal machinery to increase the metabolites needed for the biosynthesis of the cannabinoid.  Beyond this patent, we are actively pursuing additional patent applications to further protect our know-how in cannabinoid manufacturing through biosynthesis.  These patent applications collectively represent the culmination of three years of dedicated time and resource investment by an extended scientific team.”

The PCT is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states.  There are 151 member countries within the PCT, enabling near-global patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India, as well as many others.

About InMed:
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.  Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking information in this news release includes statements about: a PCT filing providing intellectual and commercial protection for the Company’s proprietary biosynthesis platform technology; undertaking scale-up activities associated with the Company’s biosynthesis program; pursuing additional patent applications to further protect the Company’s know-how in cannabinoid manufacturing through biosynthesis; and the expected fundamental value drivers of the Company.